|
1
|
Kaplon H and Reichert JM: Antibodies to
watch in 2018. MAbs. 10:183–203. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ecker DM, Jones SD and Levine HL: The
therapeutic monoclonal antibody market. MAbs. 7:9–14. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lou H and Cao X: Antibody variable region
engineering for improving cancer immunotherapy. Cancer Commun
(Lond). 42:804–827. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arlotta KJ and Owen SC: Antibody and
antibody derivatives as cancer therapeutics. Wiley Interdiscip Rev
Nanomed Nanobiotechnol. 11:e15562019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nunez-Prado N, Compte M, Harwood S,
Álvarez-Méndez A, Lykkemark S, Sanz L and Álvarez-Vallina L: The
coming of age of engineered multivalent antibodies. Drug Discov
Today. 20:588–594. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jaiswal D, Verma S, Nair DT and Salunke
DM: Antibody multispecificity: A necessary evil? Mol Immunol.
152:153–161. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Steinhardt JJ, Guenaga J, Turner HL, McKee
K, Louder MK, O'Dell S, Chiang CI, Lei L, Galkin A, Andrianov AK,
et al: Rational design of a trispecific antibody targeting the
HIV-1 Env with elevated anti-viral activity. Nat Commun. 9:8772018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhong X and D'Antona AM: Recent advances
in the molecular design and applications of multispecific
biotherapeutics. Antibodies (Basel). 10:132021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Castoldi R, Jucknischke U, Pradel LP,
Arnold E, Klein C, Scheiblich S, Niederfellner G and Sustmann C:
Molecular characterization of novel trispecific ErbB-cMet-IGF1R
antibodies and their antigen-binding properties. Protein Eng Des
Sel. 25:551–559. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kamakura D, Asano R and Yasunaga M: T cell
bispecific antibodies: An antibody-based delivery system for
inducing antitumor immunity. Pharmaceuticals (Basel). 14:11722021.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ferrini S, Cambiaggi A, Cantoni C,
Canevari S, Mezzanzanica D, Colnaghi MI and Moretta L: Targeting of
T or NK lymphocytes against tumor cells by bispecific monoclonal
antibodies: Role of different triggering molecules. Int J Cancer
Suppl. 7:15–18. 1992.PubMed/NCBI
|
|
12
|
Asano R, Sone Y, Makabe K, Tsumoto K,
Hayashi H, Katayose Y, Unno M, Kudo T and Kumagai I: Humanization
of the bispecific epidermal growth factor receptor × CD3 diabody
and its efficacy as a potential clinical reagent. Clin Cancer Res.
12:4036–4042. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Asano R, Kuroki Y, Honma S, Akabane M,
Watanabe S, Mayuzumi S, Hiyamuta S, Kumagai I and Sode K:
Comprehensive study of domain rearrangements of single-chain
bispecific antibodies to determine the best combination of
configurations and microbial host cells. MAbs. 10:854–863. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Asano R, Nakayama M, Kawaguchi H, Kubota
T, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T and
Kumagai I: Construction and humanization of a functional bispecific
EGFR CD16 diabody using a refolding system. FEBS J. 279:223–233.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kuwahara A, Nagai K, Nakanishi T, Kumagai
I and Asano R: Functional domain order of an anti-EGFR × Anti-CD16
bispecific diabody involving NK cell activation. Int J Mol Sci.
21:89142020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Meermeier EW, Welsh SJ, Sharik ME, Du MT,
Garbitt VM, Riggs DL, Shi CX, Stein CK, Bergsagel M, Chau B, et al:
Tumor burden limits bispecific antibody efficacy through T cell
exhaustion averted by concurrent cytotoxic therapy. Blood Cancer
Discov. 2:354–369. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Beha N, Harder M, Ring S, Kontermann RE
and Müller D: IL15-based trifunctional antibody-fusion proteins
with costimulatory TNF-superfamily ligands in the single-chain
format for cancer immunotherapy. Mol Cancer Ther. 18:1278–1288.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu L, Seung E, Xu L, Rao E, Lord DM, Wei
RR, Cortez-Retamozo V, Ospina B, Posternak V, Ulinski G, et al:
Trispecific antibodies enhance the therapeutic efficacy of
tumor-directed T cells through T cell receptor co-stimulation. Nat
Cancer. 1:86–98. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Geissler K, Fornara P, Lautenschlager C,
Holzhausen HJ, Seliger B and Riemann D: Immune signature of tumor
infiltrating immune cells in renal cancer. Oncoimmunology.
4:e9850822015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Asano R, Nagai K, Makabe K, Takahashi K,
Kumagai T, Kawaguchi H, Ogata H, Arai K, Umetsu M and Kumagai I:
Structural considerations for functional anti-EGFR × anti-CD3
bispecific diabodies in light of domain order and binding affinity.
Oncotarget. 9:13884–13893. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miyazaki J, Takaki S, Araki K, Tashiro F,
Tominaga A, Takatsu K and Yamamura K: Expression vector system
based on the chicken beta-actin promoter directs efficient
production of interleukin-5. Gene. 79:269–277. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Asano R, Shimomura I, Konno S, Ito A,
Masakari Y, Orimo R, Taki S, Arai K, Ogata H, Okada M, et al:
Rearranging the domain order of a diabody-based IgG-like bispecific
antibody enhances its antitumor activity and improves its
degradation resistance and pharmacokinetics. MAbs. 6:1243–1254.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Saijyo S, Kudo T, Suzuki M, Katayose Y,
Shinoda M, Muto T, Fukuhara K, Suzuki T and Matsuno S:
Establishment of a new extrahepatic bile duct carcinoma cell line,
TFK-1. Tohoku J Exp Med. 177:61–71. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Asano R, Watanabe Y, Kawaguchi H, Fukazawa
H, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T and
Kumagai I: Highly effective recombinant format of a humanized
IgG-like bispecific antibody for cancer immunotherapy with
retargeting of lymphocytes to tumor cells. J Biol Chem.
282:27659–27665. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nakadate Y, Kodera Y, Kitamura Y,
Shirasawa S, Tachibana T, Tamura T and Koizumi F: KRAS mutation
confers resistance to antibody-dependent cellular cytotoxicity of
cetuximab against human colorectal cancer cells. Int J Cancer.
134:2146–2155. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xie Z, Shi M, Feng J, Yu M, Sun Y, Shen B
and Guo N: A trivalent anti-erbB2/anti-CD16 bispecific antibody
retargeting NK cells against human breast cancer cells. Biochem
Biophys Res Commun. 311:307–312. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gall FL, Kipriyanov SM, Moldenhauer G and
Little M: Di-, tri- and tetrameric single chain Fv antibody
fragments against human CD19: Effect of valency on cell binding.
FEBS Lett. 453:164–168. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sato JD, Kawamoto T, Le AD, Mendelsohn J,
Polikoff J and Sato GH: Biological effects in vitro of monoclonal
antibodies to human epidermal growth factor receptors. Mol Biol
Med. 1:511–529. 1983.PubMed/NCBI
|
|
30
|
Makabe K, Nakanishi T, Tsumoto K, Tanaka
Y, Kondo H, Umetsu M, Sone Y, Asano R and Kumagai I: Thermodynamic
consequences of mutations in vernier zone residues of a humanized
anti-human epidermal growth factor receptor murine antibody, 528. J
Biol Chem. 283:1156–1166. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li SQ, Schmitz KR, Jeffrey PD, Wiltzius
JJW, Kussie P and Ferguson KM: Structural basis for inhibition of
the epidermal growth factor receptor by cetuximab. Cancer Cell.
7:301–311. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pei XY, Holliger P, Murzin AG and Williams
RL: The 2.0-A resolution crystal structure of a trimeric antibody
fragment with noncognate VH-VL domain pairs shows a rearrangement
of VH CDR3. Proc Natl Acad Sci USA. 94:9637–9642. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dolezal O, Pearce LA, Lawrence LJ, McCoy
AJ, Hudson PJ and Kortt AA: ScFv multimers of the
anti-neuraminidase antibody NC10: Shortening of the linker in
single-chain Fv fragment assembled in V(L) to V(H) orientation
drives the formation of dimers, trimers, tetramers and higher
molecular mass multimers. Protein Eng. 13:565–574. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Power BE, Doughty L, Shapira DR, Burns JE,
Bayly AM, Caine JM, Liu Z, Scott AM, Hudson PJ and Kortt AA:
Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193
humanized antibody. Protein Sci. 12:734–747. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Le Gall F, Reusch U, Moldenhauer G, Little
M and Kipriyanov SM: Immunosuppressive properties of anti-CD3
single-chain Fv and diabody. J Immunol Methods. 285:111–127. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hudson PJ and Kortt AA: High avidity scFv
multimers; diabodies and triabodies. J Immunol Methods.
231:177–189. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Asano R, Koyama N, Hagiwara Y, Masakari Y,
Orimo R, Arai K, Ogata H, Furumoto S, Umetsu M and Kumagai I:
Anti-EGFR scFv tetramer (tetrabody) with a stable monodisperse
structure, strong anticancer effect, and a long in viFvo half-life.
FEBS Open Bio. 6:594–602. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Asano R, Ikoma K, Sone Y, Kawaguchi H,
Taki S, Hayashi H, Nakanishi T, Umetsu M, Katayose Y, Unno M, et
al: Highly enhanced cytotoxicity of a dimeric bispecific diabody,
the hEx3 tetrabody. J Biol Chem. 285:20844–20849. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Asano R, Ikoma K, Shimomura I, Taki S,
Nakanishi T, Umetsu M and Kumagai I: Cytotoxic enhancement of a
bispecific diabody by format conversion to tandem single-chain
variable fragment (taFv): The case of the hEx3 diabody. J Biol
Chem. 286:1812–1818. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Asano R, Kumagai T, Nagai K, Taki S,
Shimomura I, Arai K, Ogata H, Okada M, Hayasaka F, Sanada H, et al:
Domain order of a bispecific diabody dramatically enhances its
antitumor activity beyond structural format conversion: The case of
the hEx3 diabody. Protein Eng Des Sel. 26:359–367. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang J, Kang G, Yuan H, Cao X, Huang H and
de Marco A: Research progress and applications of multivalent,
multispecific and modified nanobodies for disease treatment. Front
Immunol. 12:8380822021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wu X and Demarest SJ: Building blocks for
bispecific and trispecific antibodies. Methods. 154:3–9. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sugiyama A, Umetsu M, Nakazawa H, Niide T,
Onodera T, Hosokawa K, Hattori S, Asano R and Kumagai I: A semi
high-throughput method for screening small bispecific antibodies
with high cytotoxicity. Sci Rep. 7:28622017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Maejima A, Ishibashi K, Kim H, Kumagai I
and Asano R: Evaluation of intercellular cross-linking abilities
correlated with cytotoxicities of bispecific antibodies with domain
rearrangements using AFM force-sensing. Biosens Bioelectron.
178:1130372021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lucchi R, Bentanachs J and Oller-Salvia B:
The masking game: Design of activatable antibodies and mimetics for
selective therapeutics and cell control. ACS Cent Sci. 7:724–738.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Maejima A, Suzuki S, Makabe K, Kumagai I
and Asano R: Incorporation of a repeated polypeptide sequence in
therapeutic antibodies as a universal masking procedure: A case
study of T cell-engaging bispecific antibodies. N Biotechnol.
77:80–89. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Schlereth B, Fichtner I, Lorenczewski G,
Kleindienst P, Brischwein K, da Silva A, Kufer P, Lutterbuese R,
Junghahn I, Kasimir-Bauer S, et al: Eradication of tumors from a
human colon cancer cell line and from ovarian cancer metastases in
immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific
antibody construct. Cancer Res. 65:2882–2889. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fujii H, Tanaka Y, Nakazawa H, Sugiyama A,
Manabe N, Shinoda A, Shimizu N, Hattori T, Hosokawa K, Sujino T, et
al: Compact seahorse-shaped T cell-activating antibody for cancer
therapy. Adv Ther. 1:17000312018. View Article : Google Scholar
|
